```
* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:57:48 ON 17 NOV 2010

=> file .pensee
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'CAPLUS' ENTERED AT 14:58:11 ON 17 NOV 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:58:11 ON 17 NOV 2010

FILE 'BIOSIS' ENTERED AT 14:58:11 ON 17 NOV 2010
Copyright (c) 2010 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 14:58:11 ON 17 NOV 2010
COPYRIGHT (C) 2010 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 14:58:11 ON 17 NOV 2010
Compendex Compilation and Indexing (C) 2010
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 14:58:11 ON 17 NOV 2010
COPYRIGHT (c) 2010 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 14:58:11 ON 17 NOV 2010
COPYRIGHT (C) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 14:58:11 ON 17 NOV 2010
COPYRIGHT (c) 2010 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 14:58:11 ON 17 NOV 2010
CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

=> e krahn thomas/au
E1            2     KRAHN T R/AU
E2            2     KRAHN THOAMS/AU
E3          138 --> KRAHN THOMAS/AU
E4           11     KRAHN THOMAS A/AU
E5            2     KRAHN TIM/AU
E6            1     KRAHN TIMM H/AU
E7            4     KRAHN TIMOTHY/AU
E8            1     KRAHN TOBIAS/AU
E9            3     KRAHN U/AU
E10           4     KRAHN ULRICH G/AU
E11           7     KRAHN ULRIKE/AU
E12          38     KRAHN V/AU

=> s e2-e3
L1          140 ("KRAHN THOAMS"/AU OR "KRAHN THOMAS"/AU)

=> s l1 and masking
L2           16 L1 AND MASKING

=> dup rem l2
```

PROCESSING COMPLETED FOR L2
L3 16 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 1-16 ti

L3 ANSWER 1 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background fluorescence and luminescence in the optical analysis of biomedical assays.

L3 ANSWER 2 OF 16 USPATFULL on STN
TI Use of Activators of Soluble Guanylate Cyclase for Treating Reperfusion Damage

L3 ANSWER 3 OF 16 USPATFULL on STN
TI Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung Diseases

L3 ANSWER 4 OF 16 USPATFULL on STN
TI Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing

L3 ANSWER 5 OF 16 USPATFULL on STN
TI Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon

L3 ANSWER 6 OF 16 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L3 ANSWER 7 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays.

L3 ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
TI Masking background flourescence and luminescence in optical analysis of biomedical assays.

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Substituted alkyl uracils and thereof

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars)

L3 ANSWER 11 OF 16 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Substituted amidoalkyl-uracils and their use

L3 ANSWER 13 OF 16 USPATFULL on STN
TI MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L3 ANSWER 14 OF 16 USPATFULL on STN
TI Masking background fluorescence and luminescence in optical analysis of biomedical assays

L3 ANSWER 15 OF 16 USPATFULL on STN
TI Masking of the background fluorescence and luminescence in the

optical analysis of biomedical assays

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2010 ACS on STN
TI Masking background fluorescence and luminescence in optical analysis of biomedical assays

=> d l3 1-5 ibib abs

L3 ANSWER 1 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2010:35759 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV201000035759
TITLE: Masking background fluorescence and luminescence in the optical analysis of biomedical assays.
AUTHOR(S): Krahn, Thomas [Inventor]; Anonymous; Paffhausen, Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem, Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Schering Pharma Aktiengesellschaft
PATENT INFORMATION: US 07615376 20091110
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (NOV 10 2009)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 30 Dec 2009
Last Updated on STN: 30 Dec 2009

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

L3 ANSWER 2 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2009:333904 USPATFULL <<LOGINID::20101117>>
TITLE: Use of Activators of Soluble Guanylate Cyclase for Treating Reperfusion Damage
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL

REPUBLIC OF
Stasch, Johannes-peter, Solingen, GERMANY, FEDERAL REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Bayer Health Care, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20090298822	A1	20091203	
APPLICATION INFO.:	US 2006-922838	A1	20060706	(11)
	WO 2006-EP6600		20060706	
			20090803	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005031576	20050706

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 223
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of compounds for manufacturing a pharmaceutical product/medicament for the prophylaxis and/or treatment of reperfusion damage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2009:320321 USPATFULL <<LOGINID::20101117>>
TITLE: Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung Diseases
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Stasch, Johannes-peter, Solingen, GERMANY, FEDERAL REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20090286781	A1	20091119	
APPLICATION INFO.:	US 2006-83121	A1	20060923	(12)
	WO 2006-EP9264		20060923	
			20090610	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005047946	20051006

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Barbara A. Shimei, Director, Patents & Licensing, Bayer

HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of compounds of the formulae I-VI for manufacturing a pharmaceutical for the treatment of acute and chronic lung disorders such as the respiratory distress syndromes [acute lung injury (ALI), acute respiratory distress syndrome (ARDS)] and the treatment of COPD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2009:246966 USPATFULL <<LOGINID::20101117>>
TITLE: Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Stasch, Johannes-Peter, Solingen, GERMANY, FEDERAL REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Stelte-Ludwig, Beatrix, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20090221573	A1	20090903	
APPLICATION INFO.:	US 2006-988351	A1	20060706	(11)
	WO 2006-EP6598		20060706	
			20090512	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005031575	20050706

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for promoting wound healing by administering one or more compounds identified in the claims, and to pharmaceutical compositions containing such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2009:240402 USPATFULL <<LOGINID::20101117>>
TITLE: Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL

REPUBLIC OF
Stasch, Johannes-Peter, Solingen, GERMANY, FEDERAL REPUBLIC OF
Weimann, Gerrit, Koln, GERMANY, FEDERAL REPUBLIC OF
Thielemann, Wolfgang, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Bayer HealthCare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20090215769	A1	20090827	
APPLICATION INFO.:	US 2006-988991	A1	20060704	(11)
	WO 2006-EP6501		20060704	
			20090227	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005033370	20050716
	DE 2005-102005047945	20051006

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Barbara A. Shimei, Director, Patents & Licensing, Bayer HealthCare LLC - Pharmaceuticals, 555 White Plains Road, Third Floor, Tarrytown, NY, 10591, US
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administration of an effective amount of a compound selected from compounds of formulae I-IV, and to pharmaceutical compositions containing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 7-16 ibib abs

L3 ANSWER 7 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:111707 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV200700116299
TITLE: Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays.
AUTHOR(S): Anonymous; Krahn, Thomas [Inventor]; Paffhausen, Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem, Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Healthcare AG
PATENT INFORMATION: US 07138280 20061121
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (NOV 21 2006)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 14 Feb 2007
AB In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is

added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.

L3 ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:8482 BIOSIS <<LOGINID::20101117>>
DOCUMENT NUMBER: PREV200700017950
TITLE: Masking background flourescence and luminescence in optical analysis of biomedical assays.
AUTHOR(S): Anonymous; Krahn, Thoams [Inventor]; Paffhausen, Wolfgang [Inventor]; Schade, Andreas [Inventor]; Bechem, Martin [Inventor]; Schmidt, Delf [Inventor]
CORPORATE SOURCE: Hagen, Germany
ASSIGNEE: Bayer Healthcare AG
PATENT INFORMATION: US 07063952 20060620
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (JUN 20 2006)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Dec 2006
Last Updated on STN: 20 Dec 2006

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

L3 ANSWER 9 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2005:184036 USPATFULL <<LOGINID::20101117>>
TITLE: Substituted alkyl uracils and thereof

INVENTOR(S): Albrecht, Barbara, c/o Bayer Healthcare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF D 51368
Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Steinhagen, Henning, Sulzbach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Bayer Healthcare AG, Leverkusen, GERMANY, FEDERAL REPUBLIC OF, 51368 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050159431	A1	20050721	
APPLICATION INFO.:	US 2003-501033	A1	20030103	(10)
	WO 2003-EP27		20030103	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10201240	20020115

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel compounds of formula (I), to a method for the production thereof, and to their use as medicament active ingredients for the prophylaxis and/or treatment of diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2005:87882 USPATFULL <<LOGINID::20101117>>
TITLE: Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars)
INVENTOR(S): Albrecht, Barbara, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Handke-Erguden, Gabriele, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Jensen, Axel, Velbert, GERMANY, FEDERAL REPUBLIC OF
Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Nickl, Werner, Waldkirch, GERMANY, FEDERAL REPUBLIC OF
Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Steinhagen, Henning, Suzlbach, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE

PATENT INFORMATION: US 20050075347 A1 20050407
US 7125995 B2 20061024
APPLICATION INFO.: US 2003-416622 A1 20031229 (10)
WO 2001-EP12694 20011102

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10056312	20001114

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE, WEST HAVEN, CT, 06516
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel amidoalkyl uracil derivatives of formula (I), to a method for the production thereof, and to their use as medicament active substances for the prophylaxis and/or treatment of medical disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:133996 USPATFULL <<LOGINID::20101117>>
TITLE: Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays
INVENTOR(S): Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF
Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF
Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030092081	A1	20030515
	US 7138280	B2	20061121
APPLICATION INFO.:	US 2002-263607	A1	20021003 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-966522, filed on 28 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KURT BRISCOE, NORRIS, MCLAUGHLIN & MARCUS, P.A., 220 EAST 42ND STREET, 30TH FLOOR, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4

already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2003:30956 USPATFULL <<LOGINID::20101117>>
TITLE:	Substituted amidoalkyl-uracils and their use
INVENTOR(S):	Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF Albrecht, Barbara, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Gerisch, Michael, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Handke, Gabriele, Wulfrath, GERMANY, FEDERAL REPUBLIC OF Hutter, Joachim, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Jensen, Axel, Velbert, GERMANY, FEDERAL REPUBLIC OF Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF Mittendorf, Joachim, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Oehme, Felix, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Schlemmer, Karl-Heinz, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Steinhagen, Henning, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030022905	A1	20030130	
	US 6649618	B2	20031118	
APPLICATION INFO.:	US 2001-906296	A1	20010716	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10034801	20000718
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jeffrey M. Greenman, Vice President, Patents and Licensing, Bayer Corporation, 400 Morgan Lane, West Haven, CT, 06516
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel amidoalkyl-uracil derivatives of the formula (I) ##STR1##

a process for their preparation and their use as medicaments for the prophylaxis and/or treatment of disorders are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:37557 USPATFULL <<LOGINID::20101117>>
TITLE: MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS
INVENTOR(S): KRAHN, THOMAS, HAGEN, GERMANY, FEDERAL REPUBLIC OF
PAFFHAUSEN, WOLFGANG, LEVERKUSEN, GERMANY, FEDERAL REPUBLIC OF
SCHADE, ANDREAS, ESSEN, GERMANY, FEDERAL REPUBLIC OF
BECHEM, MARTIN, WUPPERTAL, GERMANY, FEDERAL REPUBLIC OF
SCHMIDT, DELF, WUPPERTAL, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020022274	A1	20020221	
	US 6420183	B2	20020716	
APPLICATION INFO.:	US 1998-194099	A1	19981120	(9)
	WO 1997-EP2662		19970523	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NORRIS McLAUGHLIN & MARCUS, P.A., 220 EAST 42nd STREET 30TH FLOOR, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the

masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2002:27123 USPATFULL <<LOGINID::20101117>>
TITLE:	Masking background fluorescence and luminescence in optical analysis of biomedical assays
INVENTOR(S):	Krahn, Thomas, Hagen, GERMANY, FEDERAL REPUBLIC OF Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020015969	A1	20020207
	US 7063952	B2	20060620
APPLICATION INFO.:	US 2001-966137	A1	20010928 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-194099, filed on 20 Nov 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Kurt G. Briscoe, Norris McLaughlin & Marcus, P.A., 30th Floor, 220 East 42nd Street, New York, NY, 10017
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer.

The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent liganda) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2002:16874 USPATFULL <<LOGINID::20101117>>
TITLE:	Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays
INVENTOR(S):	Krahn, Thoams, Hagen, GERMANY, FEDERAL REPUBLIC OF Paffhausen, Wolfgang, Leverkusen, GERMANY, FEDERAL REPUBLIC OF Schade, Andreas, Essen, GERMANY, FEDERAL REPUBLIC OF Bechem, Martin, Wuppertal, GERMANY, FEDERAL REPUBLIC OF Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020009754	A1	20020124
APPLICATION INFO.:	US 2001-966522	A1	20010928 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-194099, filed on 20 Nov 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19621312	19960528

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Kurt G. Briscoe, Norris McLaughlin & Marcus, P.A., 30th Floor, 220 East 42nd Street, New York, NY, 10017
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6

or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2. (FIGS. 2 and 10)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1997:805887 CAPLUS <<LOGINID::20101117>>
DOCUMENT NUMBER: 128:59162
ORIGINAL REFERENCE NO.: 128:11503a,11506a
TITLE: Masking background fluorescence and luminescence in optical analysis of biomedical assays
INVENTOR(S): Krahn, Thomas; Paffhausen, Wolfgang; Schade, Andreas; Bechem, Martin; Schmidt, Delf
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Krahn, Thomas; Paffhausen, Wolfgang; Schade, Andreas; Bechem, Martin; Schmidt, Delf
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745739	A1	19971204	WO 1997-EP2662	19970523
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19621312	A1	19971204	DE 1996-19621312	19960528
CA 2256629	A1	19971204	CA 1997-2256629	19970523
CA 2256629	C	20030722		
EP 906572	A1	19990407	EP 1997-927032	19970523
EP 906572	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, FI				
JP 2000512746	T	20000926	JP 1997-541578	19970523
JP 3452068	B2	20030929		
AT 215698	T	20020415	AT 1997-927032	19970523
ES 2175416	T3	20021116	ES 1997-927032	19970523
US 20020022274	A1	20020221	US 1998-194099	19981120
US 6420183	B2	20020716		
US 20020009754	A1	20020124	US 2001-966522	20010928
US 20020015969	A1	20020207	US 2001-966137	20010928
US 7063952	B2	20060620		

```
     US 20030092081       A1    20030515    US 2002-263607          20021003
     US 7138280           B2    20061121
     US 20080318270       A1    20081225    US 2008-199317          20080827
     US 7615376           B2    20091110
PRIORITY APPLN. INFO.:                        DE 1996-19621312    A  19960528
                                              WO 1997-EP2662      W  19970523
                                              US 1998-194099      A1 19981120
                                              US 2001-966522      A3 20010928
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB   In a procedure for quant. optical anal. of fluorescently-labeled biol.
     cells a cell layer is applied to a transparent carrier at the base of a
     reaction vessel so that it is in contact with the solution containing the
     fluorescent dye.  The sensitivity of the determination may be significantly
     improved by adding to the solution a masking dye, which absorbs the
     exciting light for the fluorescent dye already present in the solution and/or
     its emitted light, and/or by applying an interlayer that is permeable to
     the solution but absorbs and/or reflects the exciting light or the emitted
     light to the cell layer at the base.  The same procedure may be used to
     improve sensitivity in quant. optical anal. of a luminescent biol. cell
     layer.  In the latter case the interlayer should be composed so that it
     possesses a high reflection factor with respect to luminescent light.
     Analogously, these procedural principles may also be applied in receptor
     studies to mask disturbing background radiation in quant. optical anal. of
     fluorescently- or luminescently-labeled participants in a reaction.  In
     this case a receptor layer is placed at the base of a reaction vessel in
     contact with a solution (supernatant 3) in which a fluorescent or luminescent
     ligand has been dissolved.  The sensitivity and accuracy of the determination
may
     be significantly improved if a masking dye which absorbs the
     exciting light for the fluorescent dye and/or its emitted light or (in
     case of luminescent ligands) the luminescent light is added to the
     supernatant.  An interlayer that is permeable to the solution but absorbs
     and/or reflects the exciting light and/or the emitted light or the
     luminescent light may be applied to the cell or receptor layer at the base
     instead of the masking dye in the solution or possibly as a
     supplementary measure.
OS.CITING REF COUNT:     14    THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
                               RECORD (14 CITINGS)
REFERENCE COUNT:          1    THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> e paffhausen wolfgang/au
E1           6     PAFFHAUSEN TOBIAS/AU
E2          14     PAFFHAUSEN W/AU
E3          21 --> PAFFHAUSEN WOLFGANG/AU
E4           1     PAFFHAUSEN WOLFGANG DIPL PHYS/AU
E5          16     PAFFI A/AU
E6          11     PAFFI ALESSANDRA/AU
E7           1     PAFFILLI MICHELANGELO/AU
E8           2     PAFFLMEYER N/AU
E9           3     PAFFMANN J V/AU
E10         11     PAFFONI A/AU
E11          1     PAFFONI ALESSANDRO/AU
E12         28     PAFFONI ALESSIO/AU

=> s e2-e3
L4          35 ("PAFFHAUSEN W"/AU OR "PAFFHAUSEN WOLFGANG"/AU)

=> s l4 and masking
L5           9 L4 AND MASKING
```

```
=> dup rem l4
PROCESSING COMPLETED FOR L4
L6            27 DUP REM L4 (8 DUPLICATES REMOVED)

=> s l4 and masking
L7             9 L4 AND MASKING

=> d l7 1-9 ti

L7   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
TI   Masking background fluorescence and luminescence in optical
     analysis of biomedical assays

L7   ANSWER 2 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background fluorescence and luminescence in the optical
     analysis of biomedical assays.

L7   ANSWER 3 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking of the background fluorescence and luminescence in the
     optical analysis of biomedical assays.

L7   ANSWER 4 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background flourescence and luminescence in optical
     analysis of biomedical assays.

L7   ANSWER 5 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
       OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L7   ANSWER 6 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays

L7   ANSWER 7 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
       ANALYSIS OF BIOMEDICAL ASSAYS

L7   ANSWER 8 OF 9  USPATFULL on STN
TI     Masking background fluorescence and luminescence in optical
       analysis of biomedical assays

L7   ANSWER 9 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays


=> e schade andreas/au
E1           8     SCHADE ANDRE/AU
E2           2     SCHADE ANDRE FRIEDRICH ALEXANDER UNIVERSITAT ERLANGEN/AU
E3          47 --> SCHADE ANDREAS/AU
E4           3     SCHADE ANDREW/AU
E5          53     SCHADE ANDREW E/AU
E6           1     SCHADE ANDREW EDWARD/AU
E7           2     SCHADE ANJA/AU
E8           3     SCHADE ANNE L/AU
E9          11     SCHADE ANNEMIEK/AU
E10          1     SCHADE ANNIKA/AU
E11          1     SCHADE ANNIKA I/AU
E12          2     SCHADE ARLEN R/AU
```

```
=> s e3
L8          47 "SCHADE ANDREAS"/AU

=> s l8 and masking
L9           9 L8 AND MASKING

=> d l9 1-9 ti

L9   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
TI   Masking background fluorescence and luminescence in optical
     analysis of biomedical assays

L9   ANSWER 2 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background fluorescence and luminescence in the optical
     analysis of biomedical assays.

L9   ANSWER 3 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking of the background fluorescence and luminescence in the
     optical analysis of biomedical assays.

L9   ANSWER 4 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background flourescence and luminescence in optical
     analysis of biomedical assays.

L9   ANSWER 5 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
       OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L9   ANSWER 6 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays

L9   ANSWER 7 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
       ANALYSIS OF BIOMEDICAL ASSAYS

L9   ANSWER 8 OF 9  USPATFULL on STN
TI     Masking background fluorescence and luminescence in optical
       analysis of biomedical assays

L9   ANSWER 9 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays


=> e bechem martin/au
E1           9     BECHEM KLAUS/AU
E2          83     BECHEM M/AU
E3         125 --> BECHEM MARTIN/AU
E4           1     BECHEM MARTIN DIPL BIOL/AU
E5           1     BECHEM N N/AU
E6           7     BECHEM PHILIP/AU
E7           1     BECHEM PHILIP C/AU
E8           2     BECHEM PHILIP CARL/AU
E9           1     BECHEM PHILLIP/AU
E10         12     BECHEM ULRICH/AU
E11          1     BECHEM ULRICH W/AU
E12          2     BECHEM ULRICH WILHELM/AU

=> s e2-e3
L10        208 ("BECHEM M"/AU OR "BECHEM MARTIN"/AU)
```

```
=> dup rem l10
PROCESSING COMPLETED FOR L10
L11         156 DUP REM L10 (52 DUPLICATES REMOVED)

=> s l11 and masking
L12          10 L11 AND MASKING

=> d l12 1-10 ti

L12  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2010 ACS on STN
TI   Masking background fluorescence and luminescence in optical
     analysis of biomedical assays

L12  ANSWER 2 OF 10  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background fluorescence and luminescence in the optical
     analysis of biomedical assays.

L12  ANSWER 3 OF 10  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking of the background fluorescence and luminescence in the
     optical analysis of biomedical assays.

L12  ANSWER 4 OF 10  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background flourescence and luminescence in optical
     analysis of biomedical assays.

L12  ANSWER 5 OF 10  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
       OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L12  ANSWER 6 OF 10  USPATFULL on STN
TI     Quinoxalinones and their use especially in the treatment of
       cardiovascular diseases

L12  ANSWER 7 OF 10  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays

L12  ANSWER 8 OF 10  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
       ANALYSIS OF BIOMEDICAL ASSAYS

L12  ANSWER 9 OF 10  USPATFULL on STN
TI     Masking background fluorescence and luminescence in optical
       analysis of biomedical assays

L12  ANSWER 10 OF 10  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays


=> e schmidt delf/au
E1           1     SCHMIDT DELBERT D/AU
E2           1     SCHMIDT DELBERT L/AU
E3         221 --> SCHMIDT DELF/AU
E4           2     SCHMIDT DELF D/AU
E5           1     SCHMIDT DELFT/AU
E6           1     SCHMIDT DELT/AU
E7           7     SCHMIDT DENISE/AU
E8           3     SCHMIDT DENISE A/AU
E9           3     SCHMIDT DENISE RODRIGUES COSTA/AU
```

```
E10           4     SCHMIDT DENISE S/AU
E11           2     SCHMIDT DENISE Z/AU
E12          53     SCHMIDT DENNIS/AU

=> s e3 and masking
L13           9 "SCHMIDT DELF"/AU AND MASKING

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14           9 DUP REM L13 (0 DUPLICATES REMOVED)

=> d l14 1-9 ti

L14  ANSWER 1 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background fluorescence and luminescence in the optical
     analysis of biomedical assays.

L14  ANSWER 2 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN THE
       OPTICAL ANALYSIS OF BIOMEDICAL ASSAYS

L14  ANSWER 3 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking of the background fluorescence and luminescence in the
     optical analysis of biomedical assays.

L14  ANSWER 4 OF 9  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
TI   Masking background flourescence and luminescence in optical
     analysis of biomedical assays.

L14  ANSWER 5 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays

L14  ANSWER 6 OF 9  USPATFULL on STN
TI     MASKING BACKGROUND FLUORESCENCE AND LUMINESCENCE IN OPTICAL
       ANALYSIS OF BIOMEDICAL ASSAYS

L14  ANSWER 7 OF 9  USPATFULL on STN
TI     Masking background fluorescence and luminescence in optical
       analysis of biomedical assays

L14  ANSWER 8 OF 9  USPATFULL on STN
TI     Masking of the background fluorescence and luminescence in the
       optical analysis of biomedical assays

L14  ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
TI   Masking background fluorescence and luminescence in optical
     analysis of biomedical assays


=> logoff  y

     (FILE 'HOME' ENTERED AT 14:57:48 ON 17 NOV 2010)

     FILE 'CAPLUS, MEDLINE, BIOSIS, BIOTECHNO, COMPENDEX, ANABSTR, CERAB,
     METADEX, USPATFULL' ENTERED AT 14:58:11 ON 17 NOV 2010
                E KRAHN THOMAS/AU
L1          140 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  ("KRAHN THOAMS"/AU OR
                "KRAHN THOMAS"/AU)
L2           16 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  L1 AND MASKING
L3           16 DUP REM L2 (0 DUPLICATES REMOVED)
```

```
                D L3 1-16 TI
                D L3 1-5 IBIB ABS
                D L3 7-16 IBIB ABS
                E PAFFHAUSEN WOLFGANG/AU
L4           35 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  ("PAFFHAUSEN W"/AU OR
                "PAFFHAUSEN WOLFGANG"/AU)
L5            9 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  L4 AND MASKING
L6           27 DUP REM L4 (8 DUPLICATES REMOVED)
L7            9 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  L4 AND MASKING
                D L7 1-9 TI
                E SCHADE ANDREAS/AU
L8           47 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  "SCHADE ANDREAS"/AU
L9            9 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  L8 AND MASKING
                D L9 1-9 TI
                E BECHEM MARTIN/AU
L10         208 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  ("BECHEM M"/AU OR "BECHEM
                MARTIN"/AU)
L11         156 DUP REM L10 (52 DUPLICATES REMOVED)
L*** DEL     71 S E2-E3
L*** DEL     17 S E2-E3
L*** DEL     63 S E2-E3
L*** DEL     54 S E2-E3
L*** DEL     54 S E2-E3
L*** DEL     54 S E2-E3
L*** DEL     54 S E2-E3
L*** DEL     54 S E2-E3
L*** DEL     54 S E2-E3
L12          10 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  L11 AND MASKING
                D L12 1-10 TI
                E SCHMIDT DELF/AU
L13           9 SEA FILE=MFE SPE=ON  ABB=ON  PLU=ON  "SCHMIDT DELF"/AU AND
                MASKING
L14           9 DUP REM L13 (0 DUPLICATES REMOVED)
                D L14 1-9 TI
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                85.22      85.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -0.85      -0.85

STN INTERNATIONAL LOGOFF AT 15:03:41 ON 17 NOV 2010
```